Navigation Links
The Leukemia & Lymphoma Society and Memgen Collaborate on CLL Clinical Trial
Date:6/18/2008

he agreement marks the first immunotherapy clinical trial funded by LLS's Therapy Acceleration Program, an innovative program designed to advance therapies with high prospects of providing near-term benefit to patients suffering from blood cancers.

About Memgen, LLC

Memgen is a biotechnology company with offices in Dallas, TX and San Diego, CA. Memgen was founded four years ago to develop non-toxic and targeted active immunotherapies for the treatment of cancers. Its lead product, ISF35, has demonstrated potent anti-leukemic activity as a single agent while being well tolerated. ISF35 generates none of the immunosuppressive activities associated with standard cancer treatments.

ISF35's results are achieved through its ability to bind to a protein found on leukemic B lymphocytes. This activates a natural immune process that causes malignant cells to become more sensitive to subsequent chemotherapy treatments. This targeted and active approach by ISF35 first makes the leukemias and lymphomas more "visible" to the human immune system. Then, ISF35 activates the immune system so that it can seek out and destroy the cancerous cells.

Memgen is now seeking corporate partners to assist in the development of the ISF35 molecule as it enters advanced stage clinical trials. For more information about Memgen, please visit http://www.memgenbio.com.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R), headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, LLS has invested more than $600 million in research specifically targeting leukemia
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
4. September is Leukemia, Lymphoma and Myeloma Awareness Month
5. The Leukemia & Lymphoma Society is Encouraged by Promising News for Myeloma Patients
6. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
7. Leukemia Drug Proves Safe and Effective Over the Long Term
8. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
9. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
10. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
11. Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... March 3, 2015  American Biosurgical, LLC ("ABI") ... cable manufacturer actively engaged in the design, development ... the world,s leading medical device companies has announced ... low volume custom medical cable manufacturer based in ... MTI brand under the name MTI Medical Cables.  ...
(Date:3/3/2015)... -- Columbia Laboratories, Inc. (Nasdaq: CBRX ) (" ... pharmaceutical company focused on pharmaceuticals for women,s health, today ... ROTH Conference, which will take place from March 8-11 ... Point, California . Management,s presentation will take place ... (12:00 p.m. Eastern Time) in the Promenade room. ...
(Date:3/3/2015)... - Sante Medical Hair Restoration is now offering the ... The ARTAS Robotic System is a state-of-the-art ... for transplantation. This latest development in minimally-invasive hair ... linear scar. "The ARTAS technology extends ... surgery." says Dr. Louis Grondin , Medical ...
Breaking Medicine Technology:American Biosurgical Acquires MTI Corporation 2No linear scar. Permanent results. 2
... Children,s Oncology Group Report Shows the Addition of ... of Death by 30% in Osteosarcoma Patients, ... IDMI ) today announced the Journal of ... 3 mifamurtide (L-MTP-PE) clinical trial,(INT-0133), entitled "Osteosarcoma: The ...
... Show Subjects Receiving,Infrequently Administered Ustekinumab Maintained Improvement from Psoriasis ... ... SAN ANTONIO, Feb. 2 One-year data from a second,double-blind, ... weeks provided sustained, clinically meaningful,improvement in the treatment of moderate ...
Cached Medicine Technology:IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 2IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 3IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 4IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 5IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 6IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 7Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis 2Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis 3Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis 4Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis 5
(Date:3/3/2015)... 03, 2015 On February 21st, the ... fabulous EcoLuxe Lounge, a day-long event that features a ... products and services. Organized by Debbie Durkin and Durkin ... placement producer, the EcoLuxe Lounge saw many notable attendees. ... on General Hospital, The Flash, Star Trek: Deep Space ...
(Date:3/3/2015)... CA (PRWEB) March 03, 2015 Findings ... , Researchers at UC Davis have developed and characterized ... cancer cells, causing them to self-destruct. This novel mechanism ... responsible for a usually fatal type of brain cancer ... cancers. , The article, to be published in ...
(Date:3/3/2015)... The Rheumatology Nurses Society (RNS) ... care and safe practice for patients with rheumatic diseases. ... biologic infusions are administered in an infusion center, provider’s ... registered nurse (RN), as defined in their State Nurse ... patients receiving these medications during a first infusion, as ...
(Date:3/3/2015)... TX (PRWEB) March 04, 2015 The ... information on the therapeutic development for Alopecia. Alopecia is ... are the two main types of alopecia. Causes for ... disorder. Symptoms of alopecia may include male pattern hair ... broken hair. Alopecia can be classified as focal or ...
(Date:3/3/2015)... March 03, 2015 Daylight Savings Time may ... Kothare, MD, has tips for parents. , Parents and their ... at 2:00 a.m. when they set their clocks forward one ... up that day -- one hour earlier -- you will ... parents should start thinking about “sleep hygiene” for their kids ...
Breaking Medicine News(10 mins):Health News:Hollywood Star Chase Masterson and Choices Recovery Discuss Substance Abuse and Treatment at 2015 Oscars 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 3Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 4Health News:Administration of Biologic Infusions: A Position Statement of the Rheumatology Nurses Society 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 4Health News:Don’t Let Daylight Savings Disrupt Your Child’s Sleep 2
... Researchers at The Wistar Institute announce the discovery of ... with human papillomavirus (HPV). Their results, in both ... inhibitors protect a tumor-suppressing protein targeted by viral proteins, ... scientists presented their findings in the April 20 issue ...
... are testing whether different doses of an established blood pressure ... in people with mild hypertension, possibly with fewer side effects ... funded with a $1.9 million grant from the National Heart ... in the United States. The study drug, carvedilol ...
... April 26 (HealthDay News) -- The fourth National Prescription Drug ... 2 p.m., the U.S. Drug Enforcement Administration says. The ... and unused prescription drugs. At the third Take-Back Day ... tons) of unwanted or expired medications at more than 5,300 ...
... WEDNESDAY, April 25 (HealthDay News) -- Urban areas contaminated decades ... of aggravated assault, according to a new study. The ... dust emitted from older vehicles that ran on leaded gasoline, ... paint could have played a role as well. ...
... rs1051730-rs16969968 genotype and objective measures of tobacco exposure, which ... entirely, mediated by level of tobacco exposure, according to ... of the National Cancer Institute . The rs1051730-rs16969968 ... smoking, lung cancer risk, and other smoking-related outcomes. Prior ...
... are proposing a new model of care collaboration ... with various emergent cardiovascular conditions which require rapid, ... mortality, in an article published April 24 in ... ST-segment elevation myocardial infarction (STEMI), non-STEMI/unstable angina, out-of-hospital ...
Cached Medicine News:Health News:Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor 2Health News:Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor 3Health News:URMC clinical trial tests new regimen for hypertension 2Health News:Leaded Gas Exposure Linked to Later Violence: Study 2Health News:Genetic variants, tobacco exposure and lung cancer risk 2Health News:Is it time for regional cardiovascular emergency care systems across the US? 2
... low cost, low volume alternative. Whole blood is ... separated from whole blood by centrifugation in a ... the Cebus single use cartridge. The cartridge is ... activate the concentrating process. Finally, the cartridge is ...
Avitene Microfibrillar Collagen Hemostat (MCH) is used in surgical procedures as an to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical....
... device restores lordosis and ... less reaming of the ... Danek's Tapered Laparoscopic Instruments ... and reproducibly place the ...
3D Cranial is the most widely used surgical navigation software. Navigate with confidence and ease with displayed Zone of Accuracy and several fully automated features. 3D Cranial offers seamless int...
Medicine Products: